Who is sponsoring NCT05937893?

NCT05937893 is sponsored by Yale University.

What drugs are being tested in NCT05937893?

Interventions in NCT05937893: Keto-ester followed by Magnetic Resonance Spectroscopic Imaging (MRSI) scans.

What condition does NCT05937893 study?

NCT05937893 studies BHB Transport, Alcohol Use Disorder.

Is NCT05937893 still recruiting?

NCT05937893 is currently completed. Last updated 11 December 2024.

Last reviewed 2024-12-11 · How we verify

NCT05937893

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metabolism in the Human Brain Following Consumption of a Keto-ester in Alcohol Use Disorder (AUD) With Proton Magnetic Resonance Spectroscopic Imaging (MRSI)

Completed NA Last updated 11 December 2024

What this trial tests

NA trial testing Keto-ester followed by Magnetic Resonance Spectroscopic Imaging (MRSI) scans in BHB Transport in 12 participants. Completed in 15 May 2024.

Timeline

14 August 2023

Primary endpoint
15 May 2024

15 May 2024

Quick facts

Lead sponsor	Yale University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	12
Start date	14 August 2023
Primary completion	15 May 2024
Estimated completion	15 May 2024
Sites	1 location across United States

Drugs / interventions tested

Keto-ester followed by Magnetic Resonance Spectroscopic Imaging (MRSI) scans

Conditions studied

BHB Transport — all drugs for BHB Transport →
Alcohol Use Disorder — all drugs for Alcohol Use Disorder →

Sponsor

Yale University

Who can join

18 and older, any sex, with BHB Transport or Alcohol Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to determine whether BHB levels in the brain will be positively associated with alcohol consumption, due to hypothesized enhancement of BHB transport into the brain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05937893 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 11 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05937893.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing